135 related articles for article (PubMed ID: 34319852)
21. Assessment of two different HER2 scoring systems and clinical relevance for colorectal cancer.
Liu F; Ren C; Jin Y; Xi S; He C; Wang F; Wang Z; Xu RH; Wang F
Virchows Arch; 2020 Mar; 476(3):391-398. PubMed ID: 31720832
[TBL] [Abstract][Full Text] [Related]
22. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
[TBL] [Abstract][Full Text] [Related]
23. Relationship between HER2 expression and tumor interstitial angiogenesis in primary gastric cancer and its effect on prognosis.
Li F; Meng G; Tan B; Chen Z; Ji Q; Wang X; Liu C; Niu S; Li Y; Liu Y
Pathol Res Pract; 2021 Jan; 217():153280. PubMed ID: 33253925
[TBL] [Abstract][Full Text] [Related]
24. Frequency of HER2/neu overexpression in adenocarcinoma of the gastrointestinal system.
Farzand S; Siddique T; Saba K; Bukhari MH
World J Gastroenterol; 2014 May; 20(19):5889-96. PubMed ID: 24914350
[TBL] [Abstract][Full Text] [Related]
25. LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
Stanisavljević L; Myklebust MP; Leh S; Dahl O
Acta Oncol; 2016 Dec; 55(12):1425-1433. PubMed ID: 27435662
[TBL] [Abstract][Full Text] [Related]
26. Death decoy receptor overexpression and increased malignancy risk in colorectal cancer.
Zong L; Chen P; Wang DX
World J Gastroenterol; 2014 Apr; 20(15):4440-5. PubMed ID: 24764685
[TBL] [Abstract][Full Text] [Related]
27. Differential Expression of HER2 and SKP2 in Benign and Malignant Colorectal Lesions.
Moussa M; Badawy A; Helal N; Hegab F; Youssef M; Aboushousha T; Al Faruok L; Elwy D
Asian Pac J Cancer Prev; 2020 Aug; 21(8):2357-2366. PubMed ID: 32856866
[TBL] [Abstract][Full Text] [Related]
28. Detection of ERBB2 Amplification by Next-Generation Sequencing Predicts HER2 Expression in Colorectal Carcinoma.
Cenaj O; Ligon AH; Hornick JL; Sholl LM
Am J Clin Pathol; 2019 Jun; 152(1):97-108. PubMed ID: 31115453
[TBL] [Abstract][Full Text] [Related]
29. HER2 status in patients with residual rectal cancer after preoperative chemoradiotherapy: the relationship with molecular results and clinicopathologic features.
Park JS; Yoon G; Kim HJ; Park SY; Choi GS; Kang MK; Kim JG; Jang JS; Seo AN
Virchows Arch; 2018 Oct; 473(4):413-423. PubMed ID: 30056472
[TBL] [Abstract][Full Text] [Related]
30. Different Clinicopathological Characteristics in Indonesian Colorectal Patients with NRAS Mutations and HER2 Over-Expression.
Lukman K; Reza AT; Hasibuan LY; Sribudiani Y; Dewayani BM; Rudiman R; Primastari E; Nugraha P
Asian Pac J Cancer Prev; 2023 Apr; 24(4):1373-1377. PubMed ID: 37116161
[TBL] [Abstract][Full Text] [Related]
31. HER2 and TOP2A Gene Amplification and Protein Expression in Upper Tract Urothelial Carcinomas.
Aumayr K; Klatte T; Neudert B; Birner P; Shariat S; Schmidinger M; Susani M; Haitel A
Pathol Oncol Res; 2018 Jul; 24(3):575-581. PubMed ID: 28755093
[TBL] [Abstract][Full Text] [Related]
32. Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancer.
Sukawa Y; Yamamoto H; Nosho K; Kunimoto H; Suzuki H; Adachi Y; Nakazawa M; Nobuoka T; Kawayama M; Mikami M; Matsuno T; Hasegawa T; Hirata K; Imai K; Shinomura Y
World J Gastroenterol; 2012 Dec; 18(45):6577-86. PubMed ID: 23236232
[TBL] [Abstract][Full Text] [Related]
33. Variability in HER2 expression between primary colorectal cancer and corresponding metastases.
Shan L; Lv Y; Bai B; Huang X; Zhu H
J Cancer Res Clin Oncol; 2018 Nov; 144(11):2275-2281. PubMed ID: 30203148
[TBL] [Abstract][Full Text] [Related]
34. Quantitative real-time PCR assay with immunohistochemical evaluation of HER2/neu oncogene in breast cancer patients and its correlation with clinicopathological findings.
Gheni N; Westenberg D
Indian J Pathol Microbiol; 2020 Feb; 63(Supplement):S123-S128. PubMed ID: 32108644
[TBL] [Abstract][Full Text] [Related]
35. Clinicopathological characteristics of human epidermal growth factor receptor 2-positive Barrett's adenocarcinoma.
Tanaka T; Fujimura A; Ichimura K; Yanai H; Sato Y; Takata K; Okada H; Kawano S; Tanabe S; Yoshino T
World J Gastroenterol; 2012 Nov; 18(43):6263-8. PubMed ID: 23180947
[TBL] [Abstract][Full Text] [Related]
36. Significance of HER2 protein expression and
Wang XY; Zheng ZX; Sun Y; Bai YH; Shi YF; Zhou LX; Yao YF; Wu AW; Cao DF
World J Gastrointest Oncol; 2019 Apr; 11(4):335-347. PubMed ID: 31040898
[TBL] [Abstract][Full Text] [Related]
37. HER2 expression in oesophageal carcinoma and Barrett's oesophagus associated adenocarcinoma: An Australian study.
Nagaraja V; Shaw N; Morey AL; Cox MR; Eslick GD
Eur J Surg Oncol; 2016 Jan; 42(1):140-8. PubMed ID: 26422587
[TBL] [Abstract][Full Text] [Related]
38. Association between Her2/neu status in colorectal carcinoma and clinicopathological features: a retrospective study using whole - tissue sections.
Kılıçarslan A; Dogan HT; Süngü N; Dogan M; Yalcin A; Dede DŞ
Pol J Pathol; 2018; 69(2):143-149. PubMed ID: 30351861
[TBL] [Abstract][Full Text] [Related]
39. The status of HER2 in colorectal carcinoma and the relation of HER2 with prognostic parameters and MSI.
Saygin I; Cakir E
Indian J Pathol Microbiol; 2022; 65(2):336-342. PubMed ID: 35435368
[TBL] [Abstract][Full Text] [Related]
40. Utility of comprehensive genomic sequencing for detecting HER2-positive colorectal cancer.
Shimada Y; Yagi R; Kameyama H; Nagahashi M; Ichikawa H; Tajima Y; Okamura T; Nakano M; Nakano M; Sato Y; Matsuzawa T; Sakata J; Kobayashi T; Nogami H; Maruyama S; Takii Y; Kawasaki T; Homma KI; Izutsu H; Kodama K; Ring JE; Protopopov A; Lyle S; Okuda S; Akazawa K; Wakai T
Hum Pathol; 2017 Aug; 66():1-9. PubMed ID: 28235632
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
